Core Viewpoint - Kangfang Biopharma/Summit presented updated data from the HARMONi study at the 2025 WCLC, showing improved overall survival (OS) with a hazard ratio (HR) of 0.78 (P=0.0332), indicating a significant trend of survival benefit compared to previous analyses [1][2] Group 1: Study Overview - The HARMONi study is a global, multicenter, randomized, double-blind, placebo-controlled Phase III trial assessing the efficacy and safety of Ivonescimab in patients with disease progression after third-generation EGFR-TKI treatment [2] - A total of 438 patients were randomized (219 per group), with a median follow-up of 22.3 months, showing a significant improvement in progression-free survival (PFS) for the Ivonescimab group (HR=0.52, P<0.001) [3] Group 2: Efficacy Results - The median OS for the Ivonescimab group was 16.8 months compared to 14.0 months for the placebo group (HR 0.79, P=0.0570) [3] - Objective response rates were 44.7% for the Ivonescimab group versus 34.2% for the placebo group, with intracranial PFS also showing improvement [3] Group 3: Safety Profile - The Ivonescimab group demonstrated good safety and tolerability, with treatment-related adverse events (TRAEs) of grade ≥3 occurring in 50.0% of patients compared to 42.2% in the placebo group [4] - The most common TRAEs were laboratory abnormalities, with no new safety signals identified [4] Group 4: Follow-Up and Trends - Extended follow-up showed further improvement in OS, particularly in North American patients, with a median OS of 17 months compared to 14 months for the control group (HR=0.84) [5] - The study indicated that patients with brain metastases had better PFS outcomes compared to those without [5] Group 5: Comparative Analysis - The HARMONi study results align with the HARMONi-A study, demonstrating consistent efficacy trends across different regions, highlighting the global market potential of Ivonescimab [6] - Both studies achieved significant clinical endpoints, confirming the drug's rapid efficacy and favorable safety profile [6] Group 6: Future Outlook - Future focus will be on the results of ongoing Phase III trials, particularly HARMONi-3 and HARMONi-7, which will be critical for the drug's commercialization prospects [7] - The company has initiated multiple Phase III studies across various cancer types, indicating a robust pipeline and potential for sustained growth [7] Group 7: Financial Projections - The company projects revenues of 34.42 billion, 51.49 billion, and 76.28 billion for 2025, 2026, and 2027, respectively, with corresponding growth rates of 62.04%, 49.62%, and 48.14% [8] - The company is expected to achieve profitability by 2026, supported by a rich pipeline of products nearing approval [8]

Market Overview - On September 12, the Hang Seng Index rose by 1.16%, closing at 26,388.16 points, with a net inflow of HKD 7.331 billion through the southbound trading channel [2] - The total trading volume for the southbound trading on that day was HKD 157.992 billion, with a net buying amount of HKD 7.331 billion [2] Southbound Trading Details - The Shanghai Stock Exchange's southbound trading had a total transaction amount of HKD 97.259 billion, with a net selling of HKD 1.487 billion; while the Shenzhen Stock Exchange's southbound trading had a transaction amount of HKD 60.733 billion, with a net buying of HKD 8.818 billion [2] - The most actively traded stock in the Shanghai southbound trading was Alibaba-W, with a transaction amount of HKD 87.744 billion and a net buying of HKD 2.076 billion, closing with a price increase of 5.44% [2] - In the Shenzhen southbound trading, Alibaba-W also led with a transaction amount of HKD 63.889 billion and a net buying of HKD 2.304 billion, maintaining the same closing price increase of 5.44% [3] Active Stocks Summary - The top ten actively traded stocks in the southbound trading included Alibaba-W, Meituan-W, and SMIC, with transaction amounts of HKD 87.744 billion, HKD 50.99 billion, and HKD 37.02 billion respectively [2] - Meituan-W had the highest net selling amount of HKD 1.635 billion, closing flat [2] - Other notable stocks included Tencent Holdings and Xiaomi Group, with transaction amounts of HKD 32.17 billion and HKD 23.17 billion respectively, and Tencent saw a net buying of HKD 0.744 billion [3] Additional Stock Performance - The stock performance of various companies showed that 8 out of the top ten stocks had net buying, with Alibaba-W leading at HKD 2.304 billion [3] - The stock of Sanofi had the highest net selling amount of HKD 0.295 billion, while its closing price increased by 1.81% [4]

Group 1 - The net buying of stocks by southbound funds includes Alibaba-W at 4.38 billion, Tencent Holdings at 0.929 billion, Pop Mart at 0.642 billion, Hua Hong Semiconductor at 0.401 billion, Kangfang Biotech at 0.225 billion, and Yaojie Ankang-B at 0.18 billion, while net selling includes Meituan-W at 1.682 billion, 3SBio at 0.294 billion, UBTECH at 0.228 billion, and Bilibili-W at 0.138 billion [1] - Southbound funds have continuously net bought Alibaba for 16 days, totaling 41.52389 billion HKD, while net selling Meituan for 4 days, totaling 2.70959 billion HKD [3] Group 2 - Alibaba and Baidu have started using self-designed chips to train their AI models, partially replacing chips produced by Nvidia. Alibaba's Tongyi Qianwen has released the next-generation foundational model architecture Qwen3-Next and open-sourced the Qwen3-Next-80B-A3B series model based on this architecture [4] - Pop Mart has launched its first gold series products under its jewelry brand popop, with the most expensive item being a gold ornament weighing approximately 41 grams, priced over 56,000 RMB. The price of the gold series products will not fluctuate with gold prices but will vary based on craftsmanship, with prices per gram mainly concentrated between 1,300 to 1,700 RMB [4] - Yaojie Ankang's stock price has surged over 18 times since its IPO price of 13.15 HKD in less than three months. The company announced that its core product, Tengrutin combined with Fulvestrant, has received clinical implied approval from the National Medical Products Administration of China for a Phase II clinical trial for recurrent or metastatic breast cancer [4] Group 3 - Meituan is considering issuing dim sum bonds, with multiple investment banks gauging fixed-income investors' interest in potential offshore RMB bonds. Discussions are still in the preliminary stages regarding details such as term, scale, and issuance timing [5] - If successfully priced, this will be Meituan's first issuance of dim sum bonds. Meituan has a 750 million USD bond with a 2.125% coupon maturing on October 28. Last September, Meituan raised a total of 2.5 billion USD through the issuance of two USD bonds [6]

Core Viewpoint - The significant surge in the stock price of药捷安康-B is attributed to the major progress of its core product, Tinengotinib, which has received clinical approval for treating specific types of breast cancer [3][4]. Company Summary - 药捷安康 is a biopharmaceutical company focused on discovering and developing innovative small molecule therapies for oncology, inflammation, and cardiovascular metabolic diseases. The company is currently in the clinical development stage and does not have main business revenue [6]. - In the first half of the year, the company reported a pre-tax loss of 123 million yuan, an improvement compared to a loss of 160 million yuan in the same period last year. Total losses for the year are projected to be 275 million yuan, with research and development expenses amounting to 244 million yuan [5][6]. Product Development - The stock price increase is primarily driven by the announcement that Tinengotinib has received clinical approval for a Phase II trial in combination with Fulvestrant for treating hormone receptor-positive, HER2-negative metastatic breast cancer [3]. - Tinengotinib is a potent MTK inhibitor targeting key pathways (FGFR/VEGFR, JAK, and Aurora kinases) and has the potential to address clinical needs for various refractory or resistant solid tumors [4]. Market Potential - The unique characteristics of Tinengotinib, being one of the few MTK inhibitors targeting multiple pathways, contribute to its attractiveness in the capital market. It has received breakthrough therapy designation from the Chinese National Medical Products Administration and fast-track designation from the FDA for cholangiocarcinoma treatment [4]. - The global market for cholangiocarcinoma (CCA) drugs is projected to reach $2 billion by 2024, with a compound annual growth rate (CAGR) of 16.2% from 2019 to 2024, and is expected to grow to $4.6 billion by 2030 [6].

Core Viewpoint - The significant surge in the stock price of药捷安康-B is attributed to the major progress of its core product, Tinengotinib, which has received clinical approval for treating specific types of breast cancer, reflecting the rapid rise of China's innovative drug industry in the global market [4][5]. Group 1: Stock Performance - On September 12, the stock price of药捷安康-B surged over 130% at one point, closing with a 77.09% increase, bringing its market capitalization to 764.03 billion HKD [1]. - Since September 10, the stock has experienced a maximum increase of over 250% in just three trading days [4]. Group 2: Clinical Developments - The stock price increase is primarily driven by the announcement of clinical trial breakthroughs for Tinengotinib, which has received clinical approval for treating hormone receptor-positive, HER2-negative metastatic breast cancer [5]. - Additionally, Tinengotinib is involved in a clinical study for treating advanced liver cancer, with the first patient having been dosed recently [5]. Group 3: Product Uniqueness and Market Potential - Tinengotinib is a unique MTK inhibitor targeting FGFR, VEGFR, JAK, and Aurora pathways, making it effective for various hard-to-treat cancers [6]. - The product has received multiple designations, including breakthrough therapy and orphan drug status from regulatory agencies, highlighting its potential in the market [6]. Group 4: Financial Performance - In the first half of the year, the company reported a pre-tax loss of 123 million CNY, an improvement from a loss of 160 million CNY in the same period last year [8]. - The company's other income decreased by 65.1% to 3.6 million CNY, primarily due to reduced bank interest and government subsidies [8]. Group 5: Market Outlook - The global market for cholangiocarcinoma (CCA) drugs is projected to reach 2 billion USD by 2024, with a compound annual growth rate (CAGR) of 16.2% from 2019 to 2024, indicating strong growth potential for innovative therapies like FGFR inhibitors [8].

Investment Rating - The industry rating is "Positive" for the next 12 months, expecting a growth rate exceeding 10% relative to the CSI 300 index [67][79]. Core Insights - The report highlights the impressive research outcomes of Chinese pharmaceutical companies showcased at the 2025 World Lung Cancer Conference (WCLC), emphasizing the strength of innovation in the sector. It also notes that Heng Rui has further advanced its overseas licensing strategy through the NewCo model [9][67]. - The report suggests continuous monitoring of the R&D progress of Chinese pharmaceutical companies, particularly in innovative drugs and related industrial chains, benefiting from optimized procurement rules in the pharmaceutical and medical device sectors, as well as the recovery of traditional Chinese medicine and medical services due to domestic demand [9][67]. Industry News - Bai Li Tian Heng's dual-target ADC for EGFR/HER3 has shown promising results at WCLC, with a 100% overall response rate in a study involving 154 patients [18]. - BeiGene presented the latest findings from its RATIONALE studies at WCLC, demonstrating significant survival benefits for its drug in treating non-small cell lung cancer [19]. - Kangfang Biotech updated data from its HARMONi study, showing improved overall survival rates, particularly in North America [20]. Company Announcements - Heng Rui Pharma signed a licensing agreement with Braveheart Bio for the HRS-1893 project, with an upfront payment of $65 million and potential milestone payments totaling up to $1.013 billion [35]. - The new drug application for KN026 by CSPC has been accepted by the National Medical Products Administration (NMPA) [39]. - Junshi Biosciences reported positive results from its Phase III clinical trial for an anti-IL-17A monoclonal antibody [40]. Market Review - The Shanghai Composite Index rose by 2.91%, while the Shenzhen Component Index increased by 7.11%. The pharmaceutical and biological sector saw a 1.76% increase, with most sub-sectors showing positive performance [53][57]. - As of September 11, 2025, the TTM P/E ratio for the pharmaceutical and biological industry was 31.56, with a valuation premium of 148% relative to the CSI 300 [57]. Weekly Strategy - The report recommends focusing on investment opportunities in innovative drugs and medical devices, as well as sectors benefiting from domestic demand recovery, while maintaining a "Positive" industry rating [67].

Group 1 - The core viewpoint of the news highlights a significant rebound in the A+H innovative pharmaceutical sector, with both the A-share and Hong Kong ETF for innovative drugs showing gains of over 1% [1] - The Hong Kong ETF (520880) has seen a continuous inflow of capital, attracting over 1.6 billion yuan in new investments during recent market fluctuations [1][3] - Major stocks within the Hong Kong ETF have rebounded strongly, with notable increases such as a 130% surge in the stock of Yaojie Ankang-B, which ultimately closed up 77.09% [3][4] Group 2 - The recent rebalancing of the Hong Kong ETF index has excluded CXO companies, focusing solely on innovative drug development, which is expected to enhance the index's ability to reflect industry trends accurately [5] - The index's adjustments allow for the inclusion of smaller-cap potential stocks, such as Yaojie Ankang-B, which has shown remarkable performance since its inclusion [5][6] - China's innovative drug development is gaining momentum, with the country now holding over 20% of the global pipeline for new drugs, positioning it as the second-largest in the world [6]

Group 1 - On September 12, 2025, Alibaba-W (09988), Meituan-W (03690), and SMIC (00981) were the top three companies by trading volume in the Southbound Stock Connect, with transaction amounts of 87.74 billion, 50.99 billion, and 37.02 billion respectively [1] - In the Southbound Stock Connect for Shenzhen-Hong Kong, Alibaba-W (09988), Tencent Holdings (00700), and Xiaomi Group-W (01810) led the trading volume, with transaction amounts of 63.89 billion, 32.17 billion, and 23.17 billion respectively [1] Group 2 - In the Southbound Stock Connect (Hong Kong), the top active trading companies included: - Alibaba-W (09988) with a net buy of +20.76 billion - Tencent Holdings (00700) with a net buy of +1.85 billion - Meituan-W (03690) with a net sell of -16.35 billion [2] - In the Southbound Stock Connect (Shenzhen), the top active trading companies included: - Alibaba-W (09988) with a net buy of +23.04 billion - Tencent Holdings (00700) with a net buy of +7.44 billion - Meituan-W (03690) with a net sell of -46.59 million [2]

每经AI快讯，9月12日，恒生指数上涨1.16%。南向资金今日净买入73.31亿港元。 （记者 陈鹏程） 免责声明：本文内容与数据仅供参考，不构成投资建议，使用前请核实。据此操作，风险自担。 南向资金成交活跃个股榜单中，净买入个股共9只，金额最多的是阿里巴巴-W（9988.HK，收盘价： 151.1港元），净买入43.804亿港元；净卖出个股共4只，金额最多的是美团-W（3690.HK，收盘价： 96.55港元），净卖出16.820亿港元。 | 南向资金今日成交活跃个股榜单 | | --- | | 代码 | 简称 | 收盘价 | 涨跌幅 | 净买入金额 | | | --- | --- | --- | --- | --- | --- | | | | (港元) | (%) | (亿港元) | | | 9988.HK | 阿里巴巴-W | 151.1 | 5.44 | 43.80 | = | | 0700.HK | 腾讯控股 | 643.5 | 2.22 | 9.29 | . | | 9992.HK | 泡泡玛特 | 276.8 | 1.24 | 6.42 | = | | 1347.HK | 华虹半导体 | 50. ...

Core Viewpoint - The Hong Kong innovative drug sector has rebounded significantly after a previous decline, with several companies experiencing substantial stock price increases, indicating a positive market sentiment despite concerns over potential restrictions from the U.S. on Chinese innovative drugs [2][3][4]. Group 1: Market Performance - After a drop of approximately 3.82% in the innovative drug sector, stocks like Nocera (09969.HK) surged over 14%, nearing historical highs, while others like Hutchison China MediTech (00013.HK) and Zai Lab (09688.HK) also saw significant gains [3][4]. - The A-share market mirrored this trend, with the innovative drug index rising by 1.08%, and notable stocks like Nocera-U (688428.SH) increasing over 12% [3][4]. - Since April 9, the A-share and Hong Kong innovative drug sectors have shown strong growth, with the A-share index up 62% and the Hong Kong index up over 130% as of September 12 [4]. Group 2: Company Developments - Several pharmaceutical companies have acknowledged the rumors regarding U.S. restrictions but believe these do not currently impact the prospects for Chinese innovative drugs entering international markets [4][6]. - Key catalysts for stock price increases include recent approvals for new drugs, such as Nocera's approval for a treatment in Singapore, and positive earnings reports from companies like BeiGene and Innovent Biologics [6][11]. Group 3: Financial Performance - The innovative drug sector is entering a new cycle driven by profitability, with many companies reporting significant revenue growth. For instance, 62% of companies in the sector reported positive revenue growth, and 28% achieved positive net profit [8][11]. - In the first half of 2025, the total revenue for 50 Hong Kong-listed innovative drug companies reached 44.9 billion HKD, a year-on-year increase of 31.48%, with net profits rising by 128.4% [8][11]. - Major companies like BeiGene and Innovent Biologics have reported revenue growth exceeding 40%, marking a significant turnaround in their financial performance [11][12]. Group 4: Policy and Regulatory Environment - Recent policy changes have been favorable for the innovative drug sector, with the National Medical Products Administration optimizing clinical trial review processes to support the development of innovative drugs [3][13]. - The introduction of mechanisms to reduce supply disruption risks in drug procurement policies is expected to benefit innovative drug companies by allowing for a broader evaluation of production quality and supply capabilities [13].